Lycosyl™ works without any pharmacological, immunological or metabolic action or effects on the human body

All clinical studies consistently demonstrated that Lycosyl has a good safety profile and is well tolerated in the subjects. No serious adverse effects related to the treatment were observed and no sign of toxicity was observed in the acute and chronic toxicological animal studies.

Lycosylrelieves abdominal bloating in the upper and lower GI tract and promotes the growth of good bacteria without any pharmacological, immunological or metabolic action or effects on the human body. This non-systemic mechanism of action has earned the products made with Lycosyl™, the certification as a Class IIa medical device* under the Medical Device Directive 93/42/EEC.


* What is a Medical Device?

A medical device is amongst others defined as any article, whether used alone or in combination, intended by the manufacturer to be used for human beings for the purpose of: prevention, monitoring, treatment or alleviation of disease and which achieves its principal intended action in or on the human body, not through any pharmacological, immunological or metabolic means, but which may be assisted in its function by such means.

 

Previous | Next

 
Copyright © 2013 by InQpharm Group. All rights reserved. Last updated: July 2013 | ID: MLY/TM/EN/13/001
Lycosyl and InQpharm are trademarks of the InQpharm group of companies.